https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37846686&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37846686</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-2137</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>5</Issue><PubDate><MedlineDate>2023 Auguest</MedlineDate></PubDate></JournalIssue><Title>Zhongguo shi yan xue ye xue za zhi</Title><ISOAbbreviation>Zhongguo Shi Yan Xue Ye Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Clinical Characteristics and Correlation with Prognosis of DLBCL with Bone Marrow Involvement and Chromosomal Abnormalities].</ArticleTitle><Pagination><StartPage>1366</StartPage><EndPage>1371</EndPage><MedlinePgn>1366-1371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.19746/j.cnki.issn.1009-2137.2023.05.018</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the clinical characteristics of diffuse large B-cell lymphoma(DLBCL) patients with bone marrow involvement and chromosome abnormalities, and further analyze the correlation between the degree of chromosome abnormality and prognosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The clinical data of 88 patients diagnosed with DLBCL with bone marrow involvement and complete chromosomal findings in Shanxi Province Cancer Hospital were retrospectively analyzed. The &#x3c7;<sup>2</sup> test was used to analyze their clinical characteristics, and the Kaplan-Meier method was used in PFS and OS, and log-rank method in comparison.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Chromosome abnormalities were detected in 31 of the 88 patients(35.2%), 15 of whom had complex karyotype(17.0%). The positive rate of <i>BCL-2</i>, <i>BCL-6</i>, <i>C-MYC</i> and Ki-67&#x2265;80% was high in patients with complex karyotype, and most of them are double expressor lymphoma. Survival analysis showed that patients with complex karyotype of DLBCL had poorer PFS and OS compared to those with normal karyotype and 1-2 chromosomal abnormalities.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In DLBCL patients with bone marrow involvement and chromosome abnormalities, patients with complex karyotype have a shorter survival time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiang-Lin</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhi-Qiang</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiao-Lan</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Li-Ping</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lie-Yang</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China. E-mail: WLY6822@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhongguo Shi Yan Xue Ye Xue Za Zhi</MedlineTA><NlmUniqueID>101084424</NlmUniqueID><ISSNLinking>1009-2137</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="chi"><AbstractText Label="&#x9898;&#x76ee;" NlmCategory="UNASSIGNED">&#x9aa8;&#x9ad3;&#x6d78;&#x6da6;&#x4f34;&#x67d3;&#x8272;&#x4f53;&#x5f02;&#x5e38;&#x7684;DLBCL&#x60a3;&#x8005;&#x4e34;&#x5e8a;&#x7279;&#x5f81;&#x53ca;&#x4e0e;&#x9884;&#x540e;&#x7684;&#x76f8;&#x5173;&#x6027;&#x5206;&#x6790;.</AbstractText><AbstractText Label="&#x76ee;&#x7684;" NlmCategory="UNASSIGNED">&#x63a2;&#x8ba8;&#x9aa8;&#x9ad3;&#x6d78;&#x6da6;&#x4f34;&#x67d3;&#x8272;&#x4f53;&#x5f02;&#x5e38;&#x7684;&#x5f25;&#x6f2b;&#x5927;B&#x7ec6;&#x80de;&#x6dcb;&#x5df4;&#x7624;&#xff08;DLBCL&#xff09;&#x60a3;&#x8005;&#x7684;&#x4e34;&#x5e8a;&#x7279;&#x5f81;&#xff0c;&#x4ee5;&#x53ca;&#x67d3;&#x8272;&#x4f53;&#x5f02;&#x5e38;&#x7a0b;&#x5ea6;&#x4e0e;&#x9884;&#x540e;&#x7684;&#x76f8;&#x5173;&#x6027;.</AbstractText><AbstractText Label="&#x65b9;&#x6cd5;" NlmCategory="UNASSIGNED">&#x56de;&#x987e;&#x6027;&#x5206;&#x6790;&#x5728;&#x5c71;&#x897f;&#x7701;&#x80bf;&#x7624;&#x533b;&#x9662;&#x8bca;&#x65ad;&#x4e3a;&#x9aa8;&#x9ad3;&#x6d78;&#x6da6;&#x4e14;&#x5177;&#x6709;&#x5b8c;&#x6574;&#x67d3;&#x8272;&#x4f53;&#x7ed3;&#x679c;&#x7684;88&#x4f8b;DLBCL&#x60a3;&#x8005;&#x7684;&#x4e34;&#x5e8a;&#x8d44;&#x6599;&#xff0c;&#x91c7;&#x7528;&#x3c7;<sup>2</sup>&#x68c0;&#x9a8c;&#x5206;&#x6790;&#x5176;&#x4e34;&#x5e8a;&#x7279;&#x5f81;&#xff0c;&#x91c7;&#x7528;Kaplan-Meier&#x65b9;&#x6cd5;&#x8fdb;&#x884c;&#x65e0;&#x8fdb;&#x5c55;&#x751f;&#x5b58;(PFS)&#x548c;&#x603b;&#x4f53;&#x751f;&#x5b58;(OS)&#x5206;&#x6790;&#xff0c;log-rank&#x65b9;&#x6cd5;&#x8fdb;&#x884c;&#x6bd4;&#x8f83;&#x5206;&#x6790;.</AbstractText><AbstractText Label="&#x7ed3;&#x679c;" NlmCategory="UNASSIGNED">88&#x4f8b;&#x60a3;&#x8005;&#x4e2d;&#x6709;31&#x4f8b;&#x68c0;&#x6d4b;&#x51fa;&#x67d3;&#x8272;&#x4f53;&#x5f02;&#x5e38;(35.2&#xff05;)&#xff0c;&#x5176;&#x4e2d;&#x590d;&#x6742;&#x6838;&#x578b;&#x8005;15&#x4f8b;(17.0%)&#x3002;&#x590d;&#x6742;&#x6838;&#x578b;&#x60a3;&#x8005;<i>BCL-2</i>&#x3001;<i>BCL-6</i>&#x3001;<i>C-MYC</i>&#x3001;Ki-67&#x2265;80%&#x9633;&#x6027;&#x68c0;&#x51fa;&#x7387;&#x9ad8;&#xff0c;&#x4e14;&#x591a;&#x4e3a;&#x53cc;&#x8868;&#x8fbe;&#x3002;&#x751f;&#x5b58;&#x5206;&#x6790;&#x53d1;&#x73b0;&#x590d;&#x6742;&#x6838;&#x578b;&#x7684;DLBCL&#x60a3;&#x8005;PFS&#x548c;OS&#x660e;&#x663e;&#x5dee;&#x4e8e;&#x67d3;&#x8272;&#x4f53;&#x6b63;&#x5e38;&#x53ca;1-2&#x6761;&#x67d3;&#x8272;&#x4f53;&#x5f02;&#x5e38;&#x60a3;&#x8005;.</AbstractText><AbstractText Label="&#x7ed3;&#x8bba;" NlmCategory="UNASSIGNED">&#x9aa8;&#x9ad3;&#x6d78;&#x6da6;&#x4e14;&#x67d3;&#x8272;&#x4f53;&#x5f02;&#x5e38;&#x7684;DLBCL&#x60a3;&#x8005;&#x4e2d;&#xff0c;&#x590d;&#x6742;&#x6838;&#x578b;&#x60a3;&#x8005;&#x7684;&#x751f;&#x5b58;&#x671f;&#x66f4;&#x77ed;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chromosomal abnormalities</Keyword><Keyword MajorTopicYN="N">diffuse large B-cell lymphoma</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">survival analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>17</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>17</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37846686</ArticleId><ArticleId IdType="doi">10.19746/j.cnki.issn.1009-2137.2023.05.018</ArticleId><ArticleId IdType="pii">1009-2137(2023)05-1366-06</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>